Abstract
Currently, stroke researchers are racing to develop neuroprotective strategies that shield the brain from ischemia-induced injury. To date, neuroprotective agents that have shown promise in animal studies have failed in clinical trials. Since the pathophysiology of ischemic stroke exploits numerous pathways leading to cellular injury, a combination of neuroprotective agents may offer substantially better results than a single agent alone - by intervening in multiple mechanisms. In this paper, we consider an approach using combination therapy with normobaric oxygen (NBO) and ethanol. Studies indicate that NBO therapy improves tissue oxygenation, thereby reducing the extent of hypoxic injury and decelerating the development of tissue necrosis when administered early after stroke onset. Studies have also demonstrated that low to moderate levels of ethanol not only decrease the risk of stroke, but also reduce post-ischemic sequelae. This article reviews the history of NBO and ethanol therapies, their mechanisms of action, the results of key clinical trials, and the rationale for their use as a combination therapy in the context of stroke treatment.
Keywords: Blood brain barrier, combination therapy, ethanol, ischemia, neuroprotection, normobaric oxygen therapy, oxidative stress, reperfusion, stroke.
Current Medicinal Chemistry
Title:Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke
Volume: 22 Issue: 10
Author(s): Sweena Parmar, Shannon Moore-Langston, Vance Fredrickson, Jung-Min Kim, Radhika Rastogi, Omar Elmadoun and Yuchuan Ding
Affiliation:
Keywords: Blood brain barrier, combination therapy, ethanol, ischemia, neuroprotection, normobaric oxygen therapy, oxidative stress, reperfusion, stroke.
Abstract: Currently, stroke researchers are racing to develop neuroprotective strategies that shield the brain from ischemia-induced injury. To date, neuroprotective agents that have shown promise in animal studies have failed in clinical trials. Since the pathophysiology of ischemic stroke exploits numerous pathways leading to cellular injury, a combination of neuroprotective agents may offer substantially better results than a single agent alone - by intervening in multiple mechanisms. In this paper, we consider an approach using combination therapy with normobaric oxygen (NBO) and ethanol. Studies indicate that NBO therapy improves tissue oxygenation, thereby reducing the extent of hypoxic injury and decelerating the development of tissue necrosis when administered early after stroke onset. Studies have also demonstrated that low to moderate levels of ethanol not only decrease the risk of stroke, but also reduce post-ischemic sequelae. This article reviews the history of NBO and ethanol therapies, their mechanisms of action, the results of key clinical trials, and the rationale for their use as a combination therapy in the context of stroke treatment.
Export Options
About this article
Cite this article as:
Parmar Sweena, Moore-Langston Shannon, Fredrickson Vance, Kim Jung-Min, Rastogi Radhika, Elmadoun Omar and Ding Yuchuan, Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke, Current Medicinal Chemistry 2015; 22 (10) . https://dx.doi.org/10.2174/0929867322666150114152945
DOI https://dx.doi.org/10.2174/0929867322666150114152945 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Deoxyribozymes for Gene Knockdown
Medicinal Chemistry Reviews - Online (Discontinued) Uric Acid and Oxidative Stress
Current Pharmaceutical Design Hirudo medicinalis: Avascular Tissues for Clear-Cut Angiogenesis Studies?
Current Pharmaceutical Design Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Current Drug Therapy Improved Methods of Extraction and In Vitro Evaluation of Antimicrobial Potential of Stem Bark of Terminalia arjuna
Current Biochemical Engineering (Discontinued) Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Microarray Profiling Analysis Uncovers Common Molecular Mechanisms of Rubella Virus, Human Cytomegalovirus, and Herpes Simplex Virus Type 2 Infections in ECV304 Cells
Current Molecular Medicine The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights)
Current Pharmaceutical Design Angiotensin II and the Cardiac Complications of Diabetes Mellitus
Current Pharmaceutical Design Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses
Current Drug Targets - CNS & Neurological Disorders Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients
Current Vascular Pharmacology Understanding Respiratory Syncytial Virus Infection to Improve Treatment and Immunity
Current Molecular Medicine Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies The Role of Calcium Handling Mechanisms in Reperfusion Injury
Current Pharmaceutical Design Novel C-9, 9'-O-acyl Esters of (-)-Carinol as Free-radical Scavengers and Xanthine Oxidase Enzyme Inhibitors: Synthesis and Biological Evaluation
Medicinal Chemistry Strain Imaging Echocardiography: What Imaging Cardiologists Should Know
Current Cardiology Reviews Repositioning the Old Fungicide Ciclopirox for New Medical Uses
Current Pharmaceutical Design Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis
Current Vascular Pharmacology